Patents Assigned to MedImmune, LLC
  • Patent number: 10759849
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: September 1, 2020
    Assignee: MEDIMMUNE, LLC
    Inventors: Brett R. Sellman, Christine Tkaczyk, Melissa Hamilton, Lei Hua
  • Patent number: 10744204
    Abstract: This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: August 18, 2020
    Assignee: MedImmune, LLC
    Inventors: Changshou Gao, Godfrey Rainey, Cuihua Gao
  • Patent number: 10689437
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 23, 2020
    Assignee: MedImmune, LLC
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • Patent number: 10683340
    Abstract: The present invention relates to a method of purifying albumin-fusion proteins to reduce the level of oxidation of susceptible amino acid residues. The method comprises an affinity matrix chromatography step and an anion exchange chromatography step. The purified albumin-fusion proteins have low levels of oxidation and retain their enhanced half-life in vivo and its bioactivity. In some embodiments, the albumin-fusion protein comprises a scaffold, such as human Tenascin C scaffold. Compositions comprising the albumin-fusion protein are further disclosed.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: June 16, 2020
    Assignee: MedImmune, LLC
    Inventors: Timothy Pabst, Mariko Fonseca, Christopher Thompson, Alan Hunter, Xiangyang Wang, Liu Tie, Yiming Li
  • Publication number: 20200109191
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Application
    Filed: October 11, 2019
    Publication date: April 9, 2020
    Applicant: MedImmune, LLC
    Inventors: Brett R. SELLMAN, Christine TKACZYK, Melissa HAMILTON, Lei HUA
  • Patent number: 10519221
    Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: December 31, 2019
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary McAuliffe, Davide Corti, Antonio Lanzavecchia
  • Patent number: 10494419
    Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: December 3, 2019
    Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SA
    Inventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
  • Patent number: 10457724
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: October 29, 2019
    Assignee: MedImmune, LLC
    Inventors: Brett R. Sellman, Christine Tkaczyk, Melissa Hamilton, Lei Hua
  • Patent number: 10457732
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 29, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
  • Patent number: 10442854
    Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: October 15, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
  • Patent number: 10421811
    Abstract: Provided herein are compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies, or antigen-binding fragments thereof, and methods of making and using such compositions. In various aspects, stable coformulations of the anti-PD-L1 antibody durvalumab (MEDI4736) and the anti-CTLA-4 antibody tremelimumab are provided.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: September 24, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Jiali Du, Ambarish Shah
  • Publication number: 20190271022
    Abstract: The invention relates to a signal polypeptide for improving excretory production of a heterologous polypeptide, proteins comprising the signal polypeptide, nucleic acids encoding the signal polypeptide, and methods of using thereof.
    Type: Application
    Filed: October 26, 2017
    Publication date: September 5, 2019
    Applicant: MedImmune, LLC
    Inventors: Soojin Han, Ronald Schoner
  • Patent number: 10400035
    Abstract: The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 3, 2019
    Assignees: MedImmune, LLC, University of Helsinki
    Inventors: Kari Alitalo, Simo Syrjala, Karl Lemstrom, Ching Ching Leow, Ronald Herbst, Jane Connor
  • Patent number: 10351630
    Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of DPP-4 levels in samples obtained from human patients. The disclosure further provides novel anti-DPP-4 monoclonal antibodies that recognize human DPP-4, and assay kits comprising one or more of these antibodies.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: July 16, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Chien-Ying Chang, Xiaodong Xiao, Partha Chowdhury
  • Patent number: 10316092
    Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H5 ligand of the B7-H5:CD28H pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: June 11, 2019
    Assignees: THE JOHN HOPKINS UNIVERSITY, MEDIMMUNE, LLC
    Inventors: Sheng Yao, Lieping Chen, Linda Liu, Solomon Langermann
  • Patent number: 10259842
    Abstract: Described herein is a method for separating a recombinantly produced polypeptide from host cell protein. The method includes a step of loading a clarified cell culture supernatant that includes the recombinantly produced polypeptide and the HCP onto a Protein A chromatography column and washing the Protein A chromatography column with a wash buffer comprising a fatty acid having a chain length of at least about 6 carbon atoms, or a fatty acid salt thereof to remove HCP and then recovering the recombinantly produced polypeptide.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: April 16, 2019
    Assignees: MedImmune, LLC, Medimmune Limited
    Inventors: David Edwin Gruber, Richard Edward Turner, Jared Samuel Bee, Christopher Douglas Afdahl, Liu Tie
  • Patent number: 10232040
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: March 19, 2019
    Assignee: MEDIMMUNE, LLC
    Inventors: Rajesh Narwal, Paul Robbins, Joyson Karakunnel, Mohammed Dar
  • Publication number: 20190062411
    Abstract: The present disclosure provides MrkA binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to MrkA and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering MrkA binding proteins, e.g., antibodies or antigen-binding fragments thereof, MrkA polypeptides, immunogenic fragments thereof, or polynucleotides encoding MrkA or immunogenic fragments thereof to the subject.
    Type: Application
    Filed: March 29, 2018
    Publication date: February 28, 2019
    Applicant: MedImmune, LLC
    Inventors: Qun WANG, Saravanan RAJAN, Chew-Shun CHANG, Jenny HEIDBRINK THOMPSON, Charles Kendall STOVER, Meghan PENNINI, William DALL'ACQUA, Partha S. CHOWDHURY, Xiaodong XIAO, Hung-Yu LIN
  • Patent number: D878563
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 17, 2020
    Assignee: MedImmune, LLC.
    Inventors: Corbin Zean Clawson, Roger Wongjung Liu, Janardhanan Anand Subramony
  • Patent number: D878564
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 17, 2020
    Assignee: MedImmune, LLC.
    Inventors: Corbin Zean Clawson, Roger Wongjung Liu, Janardhanan Anand Subramony